Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

11.70USD
4:00pm EDT
Change (% chg)

$0.50 (+4.46%)
Prev Close
$11.20
Open
$11.20
Day's High
$11.85
Day's Low
$11.10
Volume
303,778
Avg. Vol
417,210
52-wk High
$15.35
52-wk Low
$4.10

TGTX.OQ

Chart for TGTX.OQ

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $747.88
Shares Outstanding(Mil.): 66.78
Dividend: --
Yield (%): --

Financials

  TGTX.OQ Industry Sector
P/E (TTM): -- 212.65 15.78
EPS (TTM): -1.83 -- --
ROI: -94.64 -7.61 -8.29
ROE: -96.73 -9.04 -7.91

BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study

* Tg therapeutics - triple combination of tg-1101, tgr-1202 and bendamustine was generally well-tolerated with only gr 3/4 event >10% being neutropenia

Jun 15 2017

BRIEF-TG Therapeutics says follow-up data for combination of TGR-1202 plus Ibrutinib

* TG Therapeutics, Inc. Announces follow-up data for combination of TGR-1202 (umbralisib) plus ibrutinib in patients with relapsed or refractory cll and mcl at the 14th international conference on malignant lymphoma

Jun 14 2017

Wall Street dips; 2017's laggards tick up, Apple slips

NEW YORK Stocks dipped on Wall Street on Monday as a drop in Apple partly offset gains in energy and financial stocks, some of the market's worst-performing sectors so far this year.

Jun 05 2017

BRIEF-TG Therapeutics gives follow-up data from chemo-free triple combination

* TG Therapeutics Inc Announces follow-up data from the chemo-free triple combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd annual meeting of the American Society Of Clinical Oncology

Jun 05 2017

BRIEF-TG Therapeutics files for potential mixed shelf offering of up to $300 mln

* TG Therapeutics inc files for potential mixed shelf offering of up to $300 million - sec filing Source text (http://bit.ly/2rq7sLa) Further company coverage:

May 26 2017

BRIEF-TG Therapeutics posts qtrly loss per share of $0.52

* TG Therapeutics Inc provides business update and reports first quarter 2017 financial results

May 05 2017

BRIEF-TG Therapeutics Inc's qtrly loss per share $0.52

* TG Therapeutics Inc provides business update and reports first quarter 2017 financial results

May 05 2017

BRIEF-TG Therapeutics Inc Q4 loss per share $0.48

* TG Therapeutics Inc announces fourth quarter and year-end 2016 financial results and business update

Mar 10 2017

BRIEF-TG Therapeutics announces proposed public offering of common stock

* TG Therapeutics announces proposed public offering of common stock Source text for Eikon: Further company coverage:

Mar 08 2017

TG Therapeutics' leukemia drug clears key study, shares pop

TG Therapeutics Inc said a combination of its experimental cancer drug, ublituximab, and approved treatment Imbruvica was found to be more effective in high-risk leukemia patients, compared with Imbruvica as a standalone therapy.

Mar 06 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $136.57 +1.36
Novartis AG (NOVN.S) CHF81.30 +0.10
Roche Holding Ltd. (ROG.S) CHF245.30 +1.20
Roche Holding Ltd. (RO.S) CHF247.50 +1.60
Merck & Co., Inc. (MRK.N) $62.94 +0.32
Bayer AG (BAYGn.DE) €112.05 +0.90
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.77 +0.53
Abbott Laboratories (ABT.N) $50.85 +1.42
Alexion Pharmaceuticals, Inc. (ALXN.OQ) $129.81 +2.51

Earnings vs. Estimates